Key Takeaways
- Volume-led revenue growth, margin squeeze: Revenue grew 13% YoY on ~30% volume growth, but EBITDA margin fell to 16.7% as higher employee, freight and job-work costs offset the benefit of lower raw material prices.
- Export prices still deep underwater: Export prices are down ~15% YoY and remain "much below" 2019 levels, with some molecules off more than 50%. The pace of decline has slowed and prices have stabilized sequentially, but a recovery is not yet in sight.
- Domestic market is the engine right now: Domestic revenue jumped to ₹97 cr from ₹64 cr YoY, driven by new product additions and strong volume offtake in fungicides and herbicides, while exports slipped to ₹75 cr from ₹87 cr.
- Hamirpur greenfield is the FY26 catalyst: The new site's first block (one intermediate, one insecticide, one herbicide) is on track to start contributing in FY26, with a long-term plan for 10–12 blocks built in phases.
- What to watch next quarter: Whether inventory days rationalize from ~170 as the Kharif-season herbicide ships in Q4, whether export pricing finally finds a floor, and any early revenue signal from the new Japanese pharma-intermediates contract.
Export Market: Price Pressure & Competitive Dynamics
- Stable demand, subdued prices: Export inquiries are coming in steadily, but realized prices remain under pressure from excess global supply. Management is focused on efficiency gains to meet those lower price points rather than waiting for a market recovery.
- Price decline vs pre-COVID: Prices have settled far below 2019 levels across the industry. In some cases the decline is 20–25%, but for certain products prices have fallen more than 50%, and a few molecules that once traded at $80–$100/kg now trade around $20/kg.
- Chinese oversupply the root cause: Chinese producers built very large capacities with government incentives of 9–13%, making them more competitive in international markets. Management believes the depth of price destruction (60–80% on some products) is unsustainable and expects some Chinese units to close, though no timeline is offered.
- Short-term order pattern: Big customers now place orders only 1–2 months ahead rather than the 6–12 month forecasts common earlier, a shift management views as mutually beneficial given violent price swings. This forces the company to hold higher inventory to meet sudden demand.
- US market growing: Exports to the US have grown to ~15% of export turnover (~₹50 cr), with Europe and Australia remaining the major markets. Management does not expect significant US tariffs on Indian agrochemicals, noting Indian prices are already steep relative to US levels.
Jain: "The prices now have settled at much below the 2019 level. They have not reached the 2019 level at all. All the products we have in the market, not only we, the overall complete agrochemical industry, the prices have declined tremendously for all the major technical products."
Domestic Market: Volume Growth & Product-Basket Expansion
- Sharp revenue jump: Domestic revenue rose to ₹97 cr from ₹64 cr YoY, driven entirely by volume as the company added new products to its basket in earlier quarters. Domestic volume growth is running ahead of export volume growth.
- Strong market-share positions: The company holds >75% market share in one product and ~50% in another when running at full capacity, concentrated in fungicides and herbicides. One of these products is slightly tight on margins and under efficiency improvement work.
- Product-mix shift underway: The company previously manufactured only two product groups; the basket has now expanded and management plans to sell new products to new customers. This diversification has reduced top-10 customer concentration from 61% of revenue in FY23 to 42%.
- Inventory build for Kharif season: Inventory days rose to ~170 because the company began building stock from August for one of its largest-selling rice herbicides, which sells during a compact 4–5 month Kharif window. Orders are now flowing and shipments will occur in Q4, so inventory days should rationalize from the March quarter onward.
- No inventory losses this year: Unlike last year, prices have been stable for many quarters, so the company has not taken inventory write-downs on the built-up stock.
Margins: Cost Headwinds Offset Raw Material Relief
- EBITDA margin at 16.7%: The decline was driven by three factors: employee expenses from upgrading the talent pool and R&D capability, a rise in ocean freight costs, and higher job-work expenses tied to increased volumes. Raw material prices also declined, but the net effect was a ~5–6% EBITDA compression.
- Other expenses breakdown: Job-work expenses doubled to ₹6 cr from ₹3 cr YoY, ocean freight rose by ₹1 cr, and power and repair costs increased in line with the 30% volume growth. These operating-cost increases absorbed much of the raw material benefit.
- Margin target maintained: Management targets an EBITDA margin range of 16–18% for the coming 2–3 quarters, implying the current level is at the lower end of the acceptable band.
- Efficiency levers: The company is working on efficiency improvements for products where margins are tight, and expects operating leverage to improve as capacity utilization rises from the current ~60% toward 85%.
Capacity Expansion: Hamirpur Greenfield & Sandila Saturation
- Hamirpur on track for FY26 contribution: The greenfield site is being built block-wise, with the first block (one intermediate, one insecticide, one herbicide) under construction. Infrastructure investment in roads, buildings, boiler, utilities, firefighting and lab means the first block's asset turn will be ~1x, improving from the second block onward.
- Long-term scale: Management envisions at least 10–12 blocks at Hamirpur over the long term, with two blocks planned for FY26. Annual capex at the site runs around ₹50 cr, all funded from internal accruals with no term debt taken to date.
- Sandila nearing saturation: The existing Sandila facility is more or less saturated, though some incremental output is possible through product-mix changes to improve capacity utilization.
- Capacity headroom: Current utilization is ~60%, and management states the existing infrastructure can support revenue of ₹1,100 cr if good export demand materializes, without requiring additional capex beyond what is already planned.
- New registrations in progress: The company has already received some registrations from the Central Insecticides Board for new products and is working on 9(3) registrations for export-oriented molecules and one import-substitution product for the domestic market, though the latter will take a long time.
Jain: "We are trying to integrate backward as much as possible because we believe that if we have to compete, we have to be Made in India first, then only in the long term, we will be sustainable."
New Business Development: Pharma Intermediates & Formulations
- Japanese pharma contract signed: A 3-year contract with Japanese companies for pharma intermediates has been secured, with first supplies expected by end-March or early April. This diversifies revenue beyond agrochemicals.
- Formulations push in international markets: The company wants to expand its formulations business abroad and is pursuing product registrations in several countries, though this is a multi-year process.
- Import-substitution alignment: The company is committed to developing chemicals that substitute imports, aligning with the government's Make in India and National Manufacturing Mission initiatives. The Union Budget's Prime Minister Dhan-Dhanya Krishi Yojana, targeting 100 agricultural districts, is expected to increase demand for advanced agrochemical solutions.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15–20% growth, driven by volume increases and new products | FY26 |
| EBITDA margin | Maintain 16–18% range | Coming 2–3 quarters |
| Hamirpur revenue contribution | First block to start generating results; full results from FY27 | FY26 onwards |
| Inventory days rationalization | Decline from ~170 days as Kharif herbicide ships | Q4 FY25 and Q1 FY26 |
| Cash conversion cycle | Decline by 20–25 days | From March quarter onwards |
| Capacity utilization | Can rise from ~60% to 85% if export demand recovers | Conditional on international demand |
| Hamirpur block build-out | Two blocks planned | FY26 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Total revenue | ₹175 cr, +13% YoY from ₹155 cr in Q3 FY24 |
| EBITDA | ₹29 cr |
| EBITDA margin | 16.7%, declined YoY due to employee expenses, ocean freight, and job work costs |
| Net profit | ₹16 cr |
| PAT margin | 9.2% |
| Export revenue | ₹75 cr, down from ₹87 cr in Q3 FY24 |
| Domestic revenue | ₹97 cr, up from ₹64 cr in Q3 FY24 |
| Technicals revenue | ₹126 cr |
| Formulations revenue | ₹46 cr |
| Sales volume growth | ~30% YoY |
| Export price decline | ~15% YoY, improved from ~20% YoY decline in Q2 FY25 |
| EBITDA margin target | 16% to 18% |
| Revenue growth target | 15% to 20% |
| Sandila capacity utilization | ~60% for 9M FY25 |
| Inventory days | ~170 days, elevated due to herbicide inventory build for Kharif season |
| Cash conversion cycle | 238 days, up from 116 days in March 2021; expected to decline by 20–25 days from March quarter onwards |
| Job work expenses | ₹6 cr, up from ₹3 cr in Q3 FY24 |
| Ocean freight increase | ~₹1 cr |
| Hamirpur capex | ~₹50 cr annually; 2 blocks planned in FY26 |
| Hamirpur block revenue potential | ₹60–70 cr per block |
| US export exposure | ~15% of export turnover, ~₹50 cr |